Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04105153

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

EGFR Positive Non-small Cell Lung Cancer Clinical Trial

Official title:
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

Clinical Trial Summary

Tyrosine kinase inhibitors (TKI) have greatly improved prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), with tumor responses in the majority of cases and a median overall survival currently exceeding 2.5 years. However, clinical courses vary widely and eventual treatment failure is inevitable. The most common resistance mechanism against first- and second-generation EGFR inhibitors is the EGFR T790M mutation, which emerges in about 50% of cases and is amenable to next-line treatment with the third-generation compound osimertinib. However, experience in everyday clinical practice shows that implementation of EGFR TKI sequencing is often problematic, for example because a considerable number of EGFR+ NSCLC patients failing first- and second-generation EGFR inhibitors do not undergo T790M mutation testing at the time of disease progression. This study will use patient records to analyze the clinical course of EGFR+ NSCLC patients treated with first- and second-generation EGFR inhibitors at the Thoraxklinik Heidelberg (Germany) during the past years. The main aim is to analyze the diagnostic and therapeutic measures, including implementation of osimertinib, taken at the time of disease progression as well as their effect on patient outcome in a real-world, routine clinical setting.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04105153
Study type Observational
Source Thoraxklinik-Heidelberg gGmbH
Contact
Status Completed
Phase
Start date April 15, 2019
Completion date December 1, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02125240 - Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Phase 3
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Not yet recruiting NCT04643847 - A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases Phase 2
Active, not recruiting NCT03126799 - A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) Phase 2
Recruiting NCT04900935 - Patient-centered, Optimal Integration of Survivorship and Palliative Care N/A
Not yet recruiting NCT02788058 - A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy Phase 2
Recruiting NCT02103257 - Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Phase 4
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Recruiting NCT05037331 - Osimertinib for Advanced EGFR-positive NSCLC Patients
Recruiting NCT04001777 - A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients Phase 1
Active, not recruiting NCT02194556 - Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Phase 4
Active, not recruiting NCT03382795 - Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients Phase 2
Recruiting NCT05089916 - Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study Phase 2
Not yet recruiting NCT06208033 - SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) Early Phase 1
Completed NCT02729298 - First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT01665417 - Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Phase 4
Not yet recruiting NCT05962021 - Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation Phase 2